Table 3.
Cox regression analysis for risk of cardiovascular mortality
| n = 353 | Model 1 | Model 2a | ||||||
|---|---|---|---|---|---|---|---|---|
| HR | 95% CI | P value | HR | 95% CI | P value | |||
| GAL4 | 1.56 | 1.38 | 1.75 | 2.8 × 10–13 | 1.38 | 1.22 | 1.56 | 4.8 × 10–7 |
| CTSD | 1.35 | 1.22 | 1.50 | 2.1 × 10–8 | 1.28 | 1.14 | 1.43 | 6.7 × 10–5 |
| FABP4 | 1.35 | 1.20 | 1.52 | 4.5 × 10–7 | 1.14 | 0.99 | 1.32 | 0.065 |
| CD163 | 1.25 | 1.12 | 1.40 | 5.4 × 10–5 | 1.21 | 1.09 | 1.36 | 0.001 |
| IGFBP2 | 1.26 | 1.12 | 1.42 | 1.7 × 10–4 | 1.18 | 1.03 | 1.35 | 0.020 |
| PAI | 1.08 | 0.97 | 1.21 | 0.16 | ||||
| PON3 | 0.92 | 0.84 | 1.02 | 0.12 | ||||
CD163, scavenger receptor cysteine rich type 1 protein M130; CTSD, cathepsin D; FABP4, fatty acid‐binding protein 4; GAL4, galectin‐4; IGFBP2, insulin‐like growth factor‐binding protein 2; PAI, plasminogen activator inhibitor 1; PON3, paraoxonase‐3.
Values are hazard ratios (HRs) and 95% confidence intervals (95% CI) for cardiovascular mortality. Model 1 is adjusted for age and sex. Model 2a is adjusted for age, sex, body mass index, systolic blood pressure, anti‐hypertensive treatment, smoking, diabetes, prevalent atrial fibrillation, prevalent heart failure, prevalent cardiovascular disease, cystatin C, total cholesterol, and high‐density lipoprotein.